Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0037315 (sleep apnea)
 8,000 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Noninvasive positive-pressure ventilation (NPPV) is the delivery of mechanical-assisted breathing without placement of an artificial airway such as an endotracheal tube or tracheostomy. During the first half of 20th century, negative-pressure ventilation (iron lung) provided mechanical ventilatory assistance. By the 1960s, however, invasive (ie, by means of an endotracheal tube) positive-pressure ventilation superseded negative-pressure ventilation as the primarily mode of support for ICU patients because of its superior delivery of support and better airway protection. Over the past decade, the use of NPPV has been integrated into the treatment of many medical diseases, largely because the development of nasal ventilation. Nasal ventilation has the potential benefit of providing ventilatory assistance with greater convenience, comfort, safety, and less cost than invasive ventilation. NPPV is delivered by a tightly fitted mask or helmet that covers the nares, face, or head. NPPV is used in various clinical settings and is beneficial in many acute medical situations. This article explores the trends regarding the use of noninvasive ventilation. It also provides a current perspective on applications in patients with acute and chronic respiratory failure, neuromuscular disease, congestive heart failure, and sleep apnea. Additionally, it discusses the general guidelines for application, monitoring, and avoidance of complications for NPPV.
 ...
PMID:Noninvasive ventilation. 1736 66

It is likely sleep apnea is highly prevalent in patients with congestive heart failure (CHF). However, as awareness is low and consensus guidelines do not exist, sleep apnea is not routinely screened for or diagnosed in CHF practice. Untreated sleep apnea may promote fatigue as well as left ventricular dysfunction, disease progression, and increased mortality. Available screening tools lack sensitivity or specificity, and there are insufficient numbers of sleep laboratories to accommodate the potentially large number of patient referrals with CHF for definitive diagnosis. In CHF patients with obstructive sleep apnea and sleepiness, treatment includes continuous positive airway pressure which may improve left ventricular function; optimal treatment for the non-sleepy patient is not established. There is no consensus regarding treatment for central sleep apnea. Studies which evaluate cardiovascular endpoints will be necessary to define management strategies for patients with CHF and either obstructive or central sleep apnea.
 ...
PMID:Sleep apnea: implications for heart failure. 1752 97

Obesity and overweight, as a part of the metabolic syndrome, are well known risk factors for the development of diabetes, hypertension, coronary heart disease, hyperlipidemia, stroke, sleep apnea syndrome, osteoarthritis and certain forms of cancer. Cardiovascular disease remains the leading killer in industrialized countries, where it accounts for 40% of deaths. Obesity is defined either by increased waist circumference, waist to hip ratio, or body mass index. Obesity results from an interaction of genes and lifestyle. As people in both developed and developing countries eat more and more energy dense food, and have ever less physical activity, the number of overweight and obese people increases to epidemic proportions. Abdominal obesity plays a key role in the pathophysiology of metabolic disorders, is associated with insulin resistance, and predicts the development of type 2 diabetes and subsequent coronary artery disease. In the general population, obesity is associated with an increased mortality, but paradoxically, a positive correlation between body mass index and survival in congestive heart failure has been reported. In secondary prevention, obesity is underrecognized, underdiagnosed and undertreated in persons with cardiovascular diseases. Weight loss and prevention of weight gain have to be considered one of the most important strategies to reduce the incidence of cardiovascular disease. Increased physical activity and appropriate diet are the cornestones of treatment. Considering the high prevalence of overweight and obesity in Croatia, there is urgent necessity to improve the level of knowledge and skills in understanding obesity by health care services, and to implement appropriate professional strategy to achieve the desired lifestyle modifications.
 ...
PMID:[Obesity--a global public health problem]. 1758 71

Three patients, who were admitted for acute decompensation of end-stage congestive heart failure (CHF), underwent nocturnal polysomnography (PSG) before, and from 7 to 80 days after, left ventricular assist device (LVAD) implantation. Moderate to severe sleep-disordered breathing (SDB) was diagnosed in all 3 patients within 48 hours of admission, consisting predominantly of Cheyne-Stokes breathing (CSB) with central sleep apnea. After LVAD implantation, despite improved hemodynamics and end-organ function, the patients continued to have moderate or severe CSB, although there was decreased time in CSB in 2 of them. These data suggest that optimization of hemodynamics and end-organ function with LVAD implantation in patients with acutely decompensated heart failure does not acutely reverse the central mechanisms underlying the diathesis for this CSB in this setting, nor does it protect patients from the potential morbidity associated with such SDB when CSB and decompensated heart failure co-exist.
 ...
PMID:Persistence of Cheyne-Stokes breathing after left ventricular assist device implantation in patients with acutely decompensated end-stage heart failure. 1761 7

Recent studies have suggested that sleep apnea-a form of sleep-disordered breathing in which sleep is repeatedly interrupted by episodes of decreased or absent breathing-may be linked to pathogenesis and progression of numerous disease states. In particular, cardiovascular conditions such as hypertension, myocardial ischemia, and congestive heart failure are associated with sleep disordered breathing. There also may be a link between diabetes and sleep apnea. While pharmacologic treatments have shown little efficacy, treatment with continuous positive airway pressure often is beneficial. Increasingly, clinicians are considering sleep apnea as a potential risk factor for many diseases and conditions.
 ...
PMID:Sleep apnea: why a good night's sleep is good for your health. 1765 56

Aldosterone concentrations are inappropriately high in many patients with hypertension, as well as in an increasing number of individuals with metabolic syndrome and sleep apnoea. A growing body of evidence suggests that aldosterone and/or activation of the MR (mineralocorticoid receptor) contributes to cardiovascular remodelling and renal injury in these conditions. In addition to causing sodium retention and increased blood pressure, MR activation induces oxidative stress, endothelial dysfunction, inflammation and subsequent fibrosis. The MR may be activated by aldosterone and cortisol or via transactivation by the AT(1) (angiotenin II type 1) receptor through a mechanism involving the EGFR (epidermal growth factor receptor) and MAPK (mitogen-activated protein kinase) pathway. In addition, aldosterone can generate rapid non-genomic effects in the heart and vasculature. MR antagonism reduces mortality in patients with CHF (congestive heart failure) and following myocardial infarction. MR antagonism improves endothelial function in patients with CHF, reduces circulating biomarkers of cardiac fibrosis in CHF or following myocardial infarction, reduces blood pressure in resistant hypertension and decreases albuminuria in hypertensive and diabetic patients. In contrast, whereas adrenalectomy improves glucose homoeostasis in hyperaldosteronism, MR antagonism may worsen glucose homoeostasis and impairs endothelial function in diabetes, suggesting a possible detrimental effect of aldosterone via non-genomic pathways.
 ...
PMID:Aldosterone and end-organ damage. 1768 82

Central (brainstem) and peripheral (carotid body) respiratory chemoreflexes act in concert to modulate breathing during sleep, maintaining blood gases (PCO2 and PO2) within narrow limits. Increases in both central and peripheral chemoreflex gain have been reported in clinical populations that experience central sleep apnoea and likely underlie the pathophysiology of this disorder. However, how central-peripheral chemoreceptor interaction affects the apparent gain of each chemoreflex is controversial. Data from our laboratory demonstrate that there is a negative interaction between central and peripheral chemoreceptors in the rat, such that brainstem hypocapnia augments peripheral chemoreflex gain in response to both carotid body PCO2 and PO2. We note that a negative interaction may also occur in humans, especially relevant in those experiencing chronic hypocapnia. Interestingly, chronic hypocapnia occurs in populations prone to central sleep apnea, such as congestive heart failure (CHF) patients and individuals sleeping at high altitude. These observations lead us to propose the novel hypothesis that a negative interaction between chemoreceptors results in an augmented peripheral chemoreceptor gain when the central chemoreceptors are hypocapnic, thereby contributing directly to breathing instability during sleep.
 ...
PMID:A negative interaction between central and peripheral respiratory chemoreceptors may underlie sleep-induced respiratory instability: a novel hypothesis. 1808 15

Continuous positive airway pressure (CPAP) is an effective treatment for obstructive sleep apnea. It is known, that there are beneficial effects on cardiac function, which might be explained by suppression of apnea and specific hemodynamic effects of CPAP. Therefore, CPAP might act as an adjunct therapy in heart failure, even in the absence of sleep apnea. In the present study, 11 patients with congestive heart failure (EF=23.1+/-6.9%) without sleep apnea (AHI 3.0+/-1.2/h) were treated with nocturnal CPAP. Cardiopulmonary exercise testing was performed at baseline and after 8.6 +/-1.3 months. All patients underwent heart catheterization and myocardial biopsy to exclude myocarditis at baseline. Five (46%) of the 11 patients did not complete the study because of poor compliance and irregular use of the CPAP device. Six (54%) of the patients used CPAP regularly (>6 h/night) and completed the study. Cardiopulmonary exercise testing showed an improvement of work load (96+/-36 Watt vs. 112+/-34 Watt; P=0.025) and VO2 peak (1227+/-443 ml vs. 1525+/-470 ml; P=0.01). Oxygen-pulse was increased, although that did not reach significance (11.2+/-4.8 ml/beat vs. 12.6+/-3.9 ml/beat). In conclusion, CPAP might have beneficial effects on exercise capacity in patients with congestive heart failure even in the absence of sleep apnea. Nevertheless, poor compliance seems to be a limiting factor.
 ...
PMID:Effects of continuous positive airway pressure on exercise capacity in chronic heart failure patients without sleep apnea. 1820 81

These practice parameters are an update of the previously published recommendations regarding the use of autotitrating positive airway pressure (APAP) devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome. Continuous positive airway pressure (CPAP) at an effective setting verified by attended polysomnography is a standard treatment for obstructive sleep apnea (OSA). APAP devices change the treatment pressure based on feedback from various patient measures such as airflow, pressure fluctuations, or measures of airway resistance. These devices may aid in the pressure titration process, address possible changes in pressure requirements throughout a given night and from night to night, aid in treatment of OSA when attended CPAP titration has not or cannot be accomplished, or improve patient comfort. A task force of the Standards of Practice Committee of the American Academy of Sleep Medicine has reviewed the literature published since the 2002 practice parameter on the use of APAP. Current recommendations follow: (1) APAP devices are not recommended to diagnose OSA; (2) patients with congestive heart failure, patients with significant lung disease such as chronic obstructive pulmonary disease; patients expected to have nocturnal arterial oxyhemoglobin desaturation due to conditions other than OSA (e.g., obesity hypoventilation syndrome); patients who do not snore (either naturally or as a result of palate surgery); and patients who have central sleep apnea syndromes are not currently candidates for APAP titration or treatment; (3) APAP devices are not currently recommended for split-night titration; (4) certain APAP devices may be used during attended titration with polysomnography to identify a single pressure for use with standard CPAP for treatment of moderate to severe OSA; (5) certain APAP devices may be initiated and used in the self-adjusting mode for unattended treatment of patients with moderate to severe OSA without significant comorbidities (CHF, COPD, central sleep apnea syndromes, or hypoventilation syndromes); (6) certain APAP devices may be used in an unattended way to determine a fixed CPAP treatment pressure for patients with moderate to severe OSA without significant comorbidities (CHF, COPD, central sleep apnea syndromes, or hypoventilation syndromes); (7) patients being treated with fixed CPAP on the basis of APAP titration or being treated with APAP must have close clinical follow-up to determine treatment effectiveness and safety; and (8) a reevaluation and, if necessary, a standard attended CPAP titration should be performed if symptoms do not resolve or the APAP treatment otherwise appears to lack efficacy.
 ...
PMID:Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report. 1822 88

Sleep-disordered breathing (SDB) describes a group of disorders characterised by abnormalities in the frequency and/or depth of breathing while asleep. The most common type is the obstructive sleep apnoea/hypopnoea syndrome (OSAHS); it affects 2-4% of the adult population and is an independent risk factor for hypertension. Another type is central sleep apnoea (CSA), which includes Cheyne-Stokes respiration; it is most commonly seen in patients with congestive heart failure and other critical illnesses including cerebrovascular accidents. There is accumulating evidence that both these types of SDB are associated with cardiac failure, arrhythmias and coronary artery disease. Treatment of OSAHS with continuous positive airway pressure (CPAP) has lowered blood pressure, reduced the frequency and severity of some arrhythmias, and improved markers of endovascular inflammation. CPAP has had a mild positive effect on left ventricular function in chronic heart failure by treating co-existent SDB, but it has not improved mortality, possibly because it does not fully treat associated CSA. Clinicians need to be aware of the increasing associations of SDB, especially OSAHS, with cardiovascular dysfunction, as treatment of co-existent SDB will not only improve sleepiness, quality of life, and driving risk, but there is growing evidence that it may also improve cardiovascular risk itself, even in non-sleepy subjects.
 ...
PMID:Sleep-disordered breathing and cardiovascular disease. 1823 Jul 47


<< Previous 1 2 3 4 5 6 7 8 9 10